Ultra-hypofractionated radiosurgery for localised prostate carcinoma

Ultra-hypofractionated radiosurgery for localised prostate carcinoma - HYPOSTAT-3

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00036292

Enrollment

175

Registered

2025-03-27

Start date

2025-12-23

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Patients with non-metastasised prostate carcinoma with indication for definitive local therapy, Ultra-hypofractionated radiosurgery with 3 fractions within 2 weeks

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Non-metastatic, histologically confirmed prostate carcinoma cT1-T2c - ISUP Grade Group 1-3 (corresponding to Gleason score 6-7) - Guideline-compliant staging - PSA < 20 ng / ml - Prostate volume < 80 cm³ - IPSS = 12 - Written consent of the patient

Exclusion criteria

Exclusion criteria: Previous radiotherapy in the pelvic area - Previous transurethral resection, laser enucleation or ablation of the prostate - Contraindications to MRI or marker implantation (e.g. gold allergy) - Relevant comorbidity, if this results in restrictions for further therapy - Inability to give consent or lack of written consent

Design outcomes

Primary

Measure	Time frame
Medium-term GU and GI toxicity after 1 year after RTOG	—

Secondary

Measure	Time frame
PSA control, acute toxicity (CTCAE), medium-term toxicity (CTCAE), quality of life, IPSS, local recurrence, distant metastasis, survival	—

Countries

Germany

Contacts

Public ContactOliver Blanck

Universitätsklinikum Schleswig-Holstein, Campus Kiel

Oliver.Blanck@uksh.de49 431 500 26666

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026